Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)

Must not show evidence of active or latent tuberculosis (TB)

Must not have received live vaccine(s) (including attenuated live vaccines and those administered intranasally) within 8 weeks of screening, or intend to during the study

Must not have been treated with steroids within 1 month of screening, or intend to during the study

Must not be immunocompromised

Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1

Must not have significant allergies to humanised monoclonal antibodies

Must not have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions

Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

Must not have had breast cancer within the past 10 years

A Study of Two Formulations of LY3074828 in Healthy Participants

What this study is about